HCTI
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Trades at a deep discount to book, but this is typical for companies with negative ROE.
- P/B of 0.14
- P/S of 0.21
- No Graham Number available due to lack of earnings
- Book value is being rapidly depleted by losses
Growth is present but currently non-monetizable.
- Strong revenue growth (44.6%)
- Positive Q/Q EPS growth trend
- Unable to convert revenue to profit
- Negative forward P/E
Historical price performance is among the worst in the dataset.
- -99.9% 1Y return
- -100% 3Y/5Y return
- Consistent earnings misses
Balance sheet is technically liquid, but the business model is bleeding capital.
- Piotroski F-Score 4/9 (Stable)
- Low Debt/Equity
- Current Ratio > 2.0
- ROE -183%
- No Altman Z-Score provided to confirm solvency
Not a dividend-paying stock.
- No dividend paid
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for HCTI and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
HCTI
Healthcare Triangle, Inc.
Primary
|
-100.0% | -100.0% | -99.9% | -98.6% | -21.6% | -2.8% |
|
HCWB
HCW Biologics Inc.
Peer
|
-99.9% | -99.4% | -96.3% | -91.0% | -30.6% | +36.0% |
|
ACON
Aclarion, Inc.
Peer
|
-100.0% | -100.0% | -82.0% | -56.9% | +22.9% | +1.8% |
|
BDRX
Biodexa Pharmaceuticals Plc
Peer
|
-100.0% | -100.0% | -95.1% | -75.6% | -24.0% | -4.0% |
|
AKAN
Akanda Corp.
Peer
|
-100.0% | -100.0% | -96.4% | -95.4% | -13.6% | -6.7% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q3 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
HCTI
Healthcare Triangle, Inc.
|
BEARISH | $2.77M | - | -183.0% | -48.8% | $2.4 | |
|
HCWB
HCW Biologics Inc.
|
BEARISH | $2.45M | - | -% | -% | $0.36 | Compare |
|
ACON
Aclarion, Inc.
|
BEARISH | $3.51M | - | -97.7% | -% | $3.33 | Compare |
|
BDRX
Biodexa Pharmaceuticals Plc
|
BEARISH | $1.8M | - | -61.8% | -% | $2.15 | Compare |
|
AKAN
Akanda Corp.
|
BEARISH | $1.73M | 0.01 | -60.9% | -266.3% | $0.82 | Compare |
Past News Coverage
Recent headlines mentioning HCTI from our newsroom.